Nitroglycerin Injection, Solution
NDC Package 51662-1386-3
Package Information
Nitroglycerin injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β-blockers; and for induction of intraoperative hypotension. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1386 and is authorized under FDA application ANDA072034.
Identification & Billing
- RxCUI: 237205 - nitroglycerin 50 MG in 10 ML Injection
- RxCUI: 237205 - 10 ML nitroglycerin 5 MG/ML Injection
- RxCUI: 237205 - 10 ML NTG 5 MG/ML Injection
- RxCUI: 237205 - 10 ML TNG 5 MG/ML Injection
- RxCUI: 237205 - nitroglycerin 50 MG per 10 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51662 - Hf Acquisition Co Llc, Dba Healthfirst
- 51662-1386 - Nitroglycerin
- 51662-1386-3 - 25 POUCH in 1 CASE / 1 VIAL, SINGLE-DOSE in 1 POUCH (51662-1386-2) / 20 mL in 1 VIAL, SINGLE-DOSE (51662-1386-1)
- 51662-1386 - Nitroglycerin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51662-1386-3 identifies a specific commercial package of 25 pouch in 1 case / 1 vial, single-dose in 1 pouch (51662-1386-2) / 20 ml in 1 vial, single-dose (51662-1386-1) of Nitroglycerin, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection, solution is formulated for intravenous use and contains nitroglycerin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on October 07, 2019. The current certification is valid through December 31, 2026.
How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662138603. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.